Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis

被引:30
作者
Brownlow, N. [1 ]
Russell, A. E. [1 ]
Saravanapavan, H. [1 ]
Wiesmann, M. [2 ]
Murray, J. M. [2 ]
Manley, P. W. [2 ]
Dibb, N. J. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England
[2] Novartis Pharma AG, Novartis Inst Biomed Res, Basel, Switzerland
基金
英国生物技术与生命科学研究理事会;
关键词
D O I
10.1038/sj.leu.2404944
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:649 / 652
页数:5
相关论文
共 20 条
[1]   Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA) [J].
Ando, Wataru ;
Hashimoto, Jun ;
Nampei, Akihide ;
Tsuboi, Hideki ;
Tateishi, Kosuke ;
Ono, Takeshi ;
Nakamura, Norimasa ;
Ochi, Takahiro ;
Yoshikawa, Hideki .
JOURNAL OF BONE AND MINERAL METABOLISM, 2006, 24 (04) :274-282
[2]   Altered bone and mineral metabolism in patients receiving imatinib mesylate [J].
Berman, E ;
Nicolaides, M ;
Maki, RG ;
Fleisher, M ;
Chanel, S ;
Scheu, K ;
Wilson, BA ;
Heller, G ;
Sauter, NP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) :2006-2013
[3]   Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580 [J].
Conway, JG ;
McDonald, B ;
Parham, J ;
Keith, B ;
Rusnak, DW ;
Shaw, E ;
Jansen, M ;
Lin, PY ;
Payne, A ;
Crosby, RM ;
Johnson, JH ;
Frick, L ;
Lin, MHJ ;
Depee, S ;
Tadepalli, S ;
Votta, B ;
James, I ;
Fuller, K ;
Chambers, TJ ;
Kull, FC ;
Chamberlain, SD ;
Hutchins, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (44) :16078-16083
[4]   Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors [J].
Dewar, AL ;
Domaschenz, RM ;
Doherty, KV ;
Hughes, TP ;
Lyons, AB .
LEUKEMIA, 2003, 17 (09) :1713-1721
[5]   Imatinib as a potential antiresorptive therapy for bone disease [J].
Dewar, Andrea L. ;
Farrugia, Amanda N. ;
Condina, Mark R. ;
To, L. Bik ;
Hughes, Timothy P. ;
Vernon-Roberts, Barrie ;
Zannettino, Andrew C. W. .
BLOOD, 2006, 107 (11) :4334-4337
[6]   Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity [J].
Dib, Iman El Hajj ;
Gallet, Marlene ;
Mentaverri, Romuald ;
Sevenet, Nicolas ;
Brazier, Michel ;
Kamel, Said .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 551 (1-3) :27-33
[7]   A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations [J].
Irvine, Katharine M. ;
Burns, Christopher J. ;
Wilks, Andrew F. ;
Su, Stephen ;
Hume, David A. ;
Sweet, Matthew J. .
FASEB JOURNAL, 2006, 20 (11) :1921-+
[8]   Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia [J].
Manley, PW ;
Cowan-Jacob, SW ;
Mestan, J .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2005, 1754 (1-2) :3-13
[9]   Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase [J].
Mol, CD ;
Dougan, DR ;
Schneider, TR ;
Skene, RJ ;
Kraus, ML ;
Scheibe, DN ;
Snell, GP ;
Zou, H ;
Sang, BC ;
Wilson, KP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (30) :31655-31663
[10]   Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation [J].
Morley, GM ;
Uden, M ;
Gullick, WJ ;
Dibb, NJ .
ONCOGENE, 1999, 18 (20) :3076-3084